title: Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
authors.affiliation: Second-year resident in the Department of Family and Community Medicine at the University of Toronto in Ontario. mazen.jazi@mail.utoronto.ca.
authors.forename: Mazen
authors.initials: M
authors.lastname: Jazi
authors.affiliation: Director of Emergency Medical Education at Toronto East General Hospital and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto.
authors.forename: George
authors.initials: G
authors.lastname: Porfiris
mesh_terms: D001786:Blood Glucose; D000068896:Canagliflozin / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007657:Ketone Bodies / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007657:Ketone Bodies; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin